Global PD-1 and PD-L1 Immunotherapy Market Research Report 2024(Status and Outlook)
Report Overview
This report provides a deep insight into the global PD-1 and PD-L1 Immunotherapy market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global PD-1 and PD-L1 Immunotherapy Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the PD-1 and PD-L1 Immunotherapy market in any manner.
Global PD-1 and PD-L1 Immunotherapy Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
AstraZeneca
Bristol-Myers Squibb
F. Hoffmann-La Roche
Merck
Pfizer
Roche
Novartis
Jiangsu HengRui Medicine
Innovent
Eli Lilly
GlaxoSmithKline
Market Segmentation (by Type)
PD-1 inhibitor
PD-L1 inhibitor
Market Segmentation (by Application)
Solid Tumors
Blood-related Tumors
Geographic Segmentation
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the PD-1 and PD-L1 Immunotherapy Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
This report provides a deep insight into the global PD-1 and PD-L1 Immunotherapy market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global PD-1 and PD-L1 Immunotherapy Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the PD-1 and PD-L1 Immunotherapy market in any manner.
Global PD-1 and PD-L1 Immunotherapy Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
AstraZeneca
Bristol-Myers Squibb
F. Hoffmann-La Roche
Merck
Pfizer
Roche
Novartis
Jiangsu HengRui Medicine
Innovent
Eli Lilly
GlaxoSmithKline
Market Segmentation (by Type)
PD-1 inhibitor
PD-L1 inhibitor
Market Segmentation (by Application)
Solid Tumors
Blood-related Tumors
Geographic Segmentation
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
- South America (Brazil, Argentina, Columbia, Rest of South America)
- The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the PD-1 and PD-L1 Immunotherapy Market
- Overview of the regional outlook of the PD-1 and PD-L1 Immunotherapy Market:
- Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
- This enables you to anticipate market changes to remain ahead of your competitors
- You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
- The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
- Provision of market value (USD Billion) data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
- Provides insight into the market through Value Chain
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- 6-month post-sales analyst support
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the PD-1 and PD-L1 Immunotherapy Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE
1.1 Market Definition and Statistical Scope of PD-1 and PD-L1 Immunotherapy
1.2 Key Market Segments
1.2.1 PD-1 and PD-L1 Immunotherapy Segment by Type
1.2.2 PD-1 and PD-L1 Immunotherapy Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 PD-1 AND PD-L1 IMMUNOTHERAPY MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global PD-1 and PD-L1 Immunotherapy Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global PD-1 and PD-L1 Immunotherapy Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 PD-1 AND PD-L1 IMMUNOTHERAPY MARKET COMPETITIVE LANDSCAPE
3.1 Global PD-1 and PD-L1 Immunotherapy Sales by Manufacturers (2019-2024)
3.2 Global PD-1 and PD-L1 Immunotherapy Revenue Market Share by Manufacturers (2019-2024)
3.3 PD-1 and PD-L1 Immunotherapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global PD-1 and PD-L1 Immunotherapy Average Price by Manufacturers (2019-2024)
3.5 Manufacturers PD-1 and PD-L1 Immunotherapy Sales Sites, Area Served, Product Type
3.6 PD-1 and PD-L1 Immunotherapy Market Competitive Situation and Trends
3.6.1 PD-1 and PD-L1 Immunotherapy Market Concentration Rate
3.6.2 Global 5 and 10 Largest PD-1 and PD-L1 Immunotherapy Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 PD-1 AND PD-L1 IMMUNOTHERAPY INDUSTRY CHAIN ANALYSIS
4.1 PD-1 and PD-L1 Immunotherapy Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF PD-1 AND PD-L1 IMMUNOTHERAPY MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 PD-1 AND PD-L1 IMMUNOTHERAPY MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global PD-1 and PD-L1 Immunotherapy Sales Market Share by Type (2019-2024)
6.3 Global PD-1 and PD-L1 Immunotherapy Market Size Market Share by Type (2019-2024)
6.4 Global PD-1 and PD-L1 Immunotherapy Price by Type (2019-2024)
7 PD-1 AND PD-L1 IMMUNOTHERAPY MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global PD-1 and PD-L1 Immunotherapy Market Sales by Application (2019-2024)
7.3 Global PD-1 and PD-L1 Immunotherapy Market Size (M USD) by Application (2019-2024)
7.4 Global PD-1 and PD-L1 Immunotherapy Sales Growth Rate by Application (2019-2024)
8 PD-1 AND PD-L1 IMMUNOTHERAPY MARKET SEGMENTATION BY REGION
8.1 Global PD-1 and PD-L1 Immunotherapy Sales by Region
8.1.1 Global PD-1 and PD-L1 Immunotherapy Sales by Region
8.1.2 Global PD-1 and PD-L1 Immunotherapy Sales Market Share by Region
8.2 North America
8.2.1 North America PD-1 and PD-L1 Immunotherapy Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe PD-1 and PD-L1 Immunotherapy Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific PD-1 and PD-L1 Immunotherapy Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America PD-1 and PD-L1 Immunotherapy Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa PD-1 and PD-L1 Immunotherapy Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 KEY COMPANIES PROFILE
9.1 AstraZeneca
9.1.1 AstraZeneca PD-1 and PD-L1 Immunotherapy Basic Information
9.1.2 AstraZeneca PD-1 and PD-L1 Immunotherapy Product Overview
9.1.3 AstraZeneca PD-1 and PD-L1 Immunotherapy Product Market Performance
9.1.4 AstraZeneca Business Overview
9.1.5 AstraZeneca PD-1 and PD-L1 Immunotherapy SWOT Analysis
9.1.6 AstraZeneca Recent Developments
9.2 Bristol-Myers Squibb
9.2.1 Bristol-Myers Squibb PD-1 and PD-L1 Immunotherapy Basic Information
9.2.2 Bristol-Myers Squibb PD-1 and PD-L1 Immunotherapy Product Overview
9.2.3 Bristol-Myers Squibb PD-1 and PD-L1 Immunotherapy Product Market Performance
9.2.4 Bristol-Myers Squibb Business Overview
9.2.5 Bristol-Myers Squibb PD-1 and PD-L1 Immunotherapy SWOT Analysis
9.2.6 Bristol-Myers Squibb Recent Developments
9.3 F. Hoffmann-La Roche
9.3.1 F. Hoffmann-La Roche PD-1 and PD-L1 Immunotherapy Basic Information
9.3.2 F. Hoffmann-La Roche PD-1 and PD-L1 Immunotherapy Product Overview
9.3.3 F. Hoffmann-La Roche PD-1 and PD-L1 Immunotherapy Product Market Performance
9.3.4 F. Hoffmann-La Roche PD-1 and PD-L1 Immunotherapy SWOT Analysis
9.3.5 F. Hoffmann-La Roche Business Overview
9.3.6 F. Hoffmann-La Roche Recent Developments
9.4 Merck
9.4.1 Merck PD-1 and PD-L1 Immunotherapy Basic Information
9.4.2 Merck PD-1 and PD-L1 Immunotherapy Product Overview
9.4.3 Merck PD-1 and PD-L1 Immunotherapy Product Market Performance
9.4.4 Merck Business Overview
9.4.5 Merck Recent Developments
9.5 Pfizer
9.5.1 Pfizer PD-1 and PD-L1 Immunotherapy Basic Information
9.5.2 Pfizer PD-1 and PD-L1 Immunotherapy Product Overview
9.5.3 Pfizer PD-1 and PD-L1 Immunotherapy Product Market Performance
9.5.4 Pfizer Business Overview
9.5.5 Pfizer Recent Developments
9.6 Roche
9.6.1 Roche PD-1 and PD-L1 Immunotherapy Basic Information
9.6.2 Roche PD-1 and PD-L1 Immunotherapy Product Overview
9.6.3 Roche PD-1 and PD-L1 Immunotherapy Product Market Performance
9.6.4 Roche Business Overview
9.6.5 Roche Recent Developments
9.7 Novartis
9.7.1 Novartis PD-1 and PD-L1 Immunotherapy Basic Information
9.7.2 Novartis PD-1 and PD-L1 Immunotherapy Product Overview
9.7.3 Novartis PD-1 and PD-L1 Immunotherapy Product Market Performance
9.7.4 Novartis Business Overview
9.7.5 Novartis Recent Developments
9.8 Jiangsu HengRui Medicine
9.8.1 Jiangsu HengRui Medicine PD-1 and PD-L1 Immunotherapy Basic Information
9.8.2 Jiangsu HengRui Medicine PD-1 and PD-L1 Immunotherapy Product Overview
9.8.3 Jiangsu HengRui Medicine PD-1 and PD-L1 Immunotherapy Product Market Performance
9.8.4 Jiangsu HengRui Medicine Business Overview
9.8.5 Jiangsu HengRui Medicine Recent Developments
9.9 Innovent
9.9.1 Innovent PD-1 and PD-L1 Immunotherapy Basic Information
9.9.2 Innovent PD-1 and PD-L1 Immunotherapy Product Overview
9.9.3 Innovent PD-1 and PD-L1 Immunotherapy Product Market Performance
9.9.4 Innovent Business Overview
9.9.5 Innovent Recent Developments
9.10 Eli Lilly
9.10.1 Eli Lilly PD-1 and PD-L1 Immunotherapy Basic Information
9.10.2 Eli Lilly PD-1 and PD-L1 Immunotherapy Product Overview
9.10.3 Eli Lilly PD-1 and PD-L1 Immunotherapy Product Market Performance
9.10.4 Eli Lilly Business Overview
9.10.5 Eli Lilly Recent Developments
9.11 GlaxoSmithKline
9.11.1 GlaxoSmithKline PD-1 and PD-L1 Immunotherapy Basic Information
9.11.2 GlaxoSmithKline PD-1 and PD-L1 Immunotherapy Product Overview
9.11.3 GlaxoSmithKline PD-1 and PD-L1 Immunotherapy Product Market Performance
9.11.4 GlaxoSmithKline Business Overview
9.11.5 GlaxoSmithKline Recent Developments
10 PD-1 AND PD-L1 IMMUNOTHERAPY MARKET FORECAST BY REGION
10.1 Global PD-1 and PD-L1 Immunotherapy Market Size Forecast
10.2 Global PD-1 and PD-L1 Immunotherapy Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe PD-1 and PD-L1 Immunotherapy Market Size Forecast by Country
10.2.3 Asia Pacific PD-1 and PD-L1 Immunotherapy Market Size Forecast by Region
10.2.4 South America PD-1 and PD-L1 Immunotherapy Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of PD-1 and PD-L1 Immunotherapy by Country
11 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2030)
11.1 Global PD-1 and PD-L1 Immunotherapy Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of PD-1 and PD-L1 Immunotherapy by Type (2025-2030)
11.1.2 Global PD-1 and PD-L1 Immunotherapy Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of PD-1 and PD-L1 Immunotherapy by Type (2025-2030)
11.2 Global PD-1 and PD-L1 Immunotherapy Market Forecast by Application (2025-2030)
11.2.1 Global PD-1 and PD-L1 Immunotherapy Sales (K Units) Forecast by Application
11.2.2 Global PD-1 and PD-L1 Immunotherapy Market Size (M USD) Forecast by Application (2025-2030)
12 CONCLUSION AND KEY FINDINGS
1.1 Market Definition and Statistical Scope of PD-1 and PD-L1 Immunotherapy
1.2 Key Market Segments
1.2.1 PD-1 and PD-L1 Immunotherapy Segment by Type
1.2.2 PD-1 and PD-L1 Immunotherapy Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 PD-1 AND PD-L1 IMMUNOTHERAPY MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global PD-1 and PD-L1 Immunotherapy Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global PD-1 and PD-L1 Immunotherapy Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 PD-1 AND PD-L1 IMMUNOTHERAPY MARKET COMPETITIVE LANDSCAPE
3.1 Global PD-1 and PD-L1 Immunotherapy Sales by Manufacturers (2019-2024)
3.2 Global PD-1 and PD-L1 Immunotherapy Revenue Market Share by Manufacturers (2019-2024)
3.3 PD-1 and PD-L1 Immunotherapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global PD-1 and PD-L1 Immunotherapy Average Price by Manufacturers (2019-2024)
3.5 Manufacturers PD-1 and PD-L1 Immunotherapy Sales Sites, Area Served, Product Type
3.6 PD-1 and PD-L1 Immunotherapy Market Competitive Situation and Trends
3.6.1 PD-1 and PD-L1 Immunotherapy Market Concentration Rate
3.6.2 Global 5 and 10 Largest PD-1 and PD-L1 Immunotherapy Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 PD-1 AND PD-L1 IMMUNOTHERAPY INDUSTRY CHAIN ANALYSIS
4.1 PD-1 and PD-L1 Immunotherapy Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF PD-1 AND PD-L1 IMMUNOTHERAPY MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 PD-1 AND PD-L1 IMMUNOTHERAPY MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global PD-1 and PD-L1 Immunotherapy Sales Market Share by Type (2019-2024)
6.3 Global PD-1 and PD-L1 Immunotherapy Market Size Market Share by Type (2019-2024)
6.4 Global PD-1 and PD-L1 Immunotherapy Price by Type (2019-2024)
7 PD-1 AND PD-L1 IMMUNOTHERAPY MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global PD-1 and PD-L1 Immunotherapy Market Sales by Application (2019-2024)
7.3 Global PD-1 and PD-L1 Immunotherapy Market Size (M USD) by Application (2019-2024)
7.4 Global PD-1 and PD-L1 Immunotherapy Sales Growth Rate by Application (2019-2024)
8 PD-1 AND PD-L1 IMMUNOTHERAPY MARKET SEGMENTATION BY REGION
8.1 Global PD-1 and PD-L1 Immunotherapy Sales by Region
8.1.1 Global PD-1 and PD-L1 Immunotherapy Sales by Region
8.1.2 Global PD-1 and PD-L1 Immunotherapy Sales Market Share by Region
8.2 North America
8.2.1 North America PD-1 and PD-L1 Immunotherapy Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe PD-1 and PD-L1 Immunotherapy Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific PD-1 and PD-L1 Immunotherapy Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America PD-1 and PD-L1 Immunotherapy Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa PD-1 and PD-L1 Immunotherapy Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 KEY COMPANIES PROFILE
9.1 AstraZeneca
9.1.1 AstraZeneca PD-1 and PD-L1 Immunotherapy Basic Information
9.1.2 AstraZeneca PD-1 and PD-L1 Immunotherapy Product Overview
9.1.3 AstraZeneca PD-1 and PD-L1 Immunotherapy Product Market Performance
9.1.4 AstraZeneca Business Overview
9.1.5 AstraZeneca PD-1 and PD-L1 Immunotherapy SWOT Analysis
9.1.6 AstraZeneca Recent Developments
9.2 Bristol-Myers Squibb
9.2.1 Bristol-Myers Squibb PD-1 and PD-L1 Immunotherapy Basic Information
9.2.2 Bristol-Myers Squibb PD-1 and PD-L1 Immunotherapy Product Overview
9.2.3 Bristol-Myers Squibb PD-1 and PD-L1 Immunotherapy Product Market Performance
9.2.4 Bristol-Myers Squibb Business Overview
9.2.5 Bristol-Myers Squibb PD-1 and PD-L1 Immunotherapy SWOT Analysis
9.2.6 Bristol-Myers Squibb Recent Developments
9.3 F. Hoffmann-La Roche
9.3.1 F. Hoffmann-La Roche PD-1 and PD-L1 Immunotherapy Basic Information
9.3.2 F. Hoffmann-La Roche PD-1 and PD-L1 Immunotherapy Product Overview
9.3.3 F. Hoffmann-La Roche PD-1 and PD-L1 Immunotherapy Product Market Performance
9.3.4 F. Hoffmann-La Roche PD-1 and PD-L1 Immunotherapy SWOT Analysis
9.3.5 F. Hoffmann-La Roche Business Overview
9.3.6 F. Hoffmann-La Roche Recent Developments
9.4 Merck
9.4.1 Merck PD-1 and PD-L1 Immunotherapy Basic Information
9.4.2 Merck PD-1 and PD-L1 Immunotherapy Product Overview
9.4.3 Merck PD-1 and PD-L1 Immunotherapy Product Market Performance
9.4.4 Merck Business Overview
9.4.5 Merck Recent Developments
9.5 Pfizer
9.5.1 Pfizer PD-1 and PD-L1 Immunotherapy Basic Information
9.5.2 Pfizer PD-1 and PD-L1 Immunotherapy Product Overview
9.5.3 Pfizer PD-1 and PD-L1 Immunotherapy Product Market Performance
9.5.4 Pfizer Business Overview
9.5.5 Pfizer Recent Developments
9.6 Roche
9.6.1 Roche PD-1 and PD-L1 Immunotherapy Basic Information
9.6.2 Roche PD-1 and PD-L1 Immunotherapy Product Overview
9.6.3 Roche PD-1 and PD-L1 Immunotherapy Product Market Performance
9.6.4 Roche Business Overview
9.6.5 Roche Recent Developments
9.7 Novartis
9.7.1 Novartis PD-1 and PD-L1 Immunotherapy Basic Information
9.7.2 Novartis PD-1 and PD-L1 Immunotherapy Product Overview
9.7.3 Novartis PD-1 and PD-L1 Immunotherapy Product Market Performance
9.7.4 Novartis Business Overview
9.7.5 Novartis Recent Developments
9.8 Jiangsu HengRui Medicine
9.8.1 Jiangsu HengRui Medicine PD-1 and PD-L1 Immunotherapy Basic Information
9.8.2 Jiangsu HengRui Medicine PD-1 and PD-L1 Immunotherapy Product Overview
9.8.3 Jiangsu HengRui Medicine PD-1 and PD-L1 Immunotherapy Product Market Performance
9.8.4 Jiangsu HengRui Medicine Business Overview
9.8.5 Jiangsu HengRui Medicine Recent Developments
9.9 Innovent
9.9.1 Innovent PD-1 and PD-L1 Immunotherapy Basic Information
9.9.2 Innovent PD-1 and PD-L1 Immunotherapy Product Overview
9.9.3 Innovent PD-1 and PD-L1 Immunotherapy Product Market Performance
9.9.4 Innovent Business Overview
9.9.5 Innovent Recent Developments
9.10 Eli Lilly
9.10.1 Eli Lilly PD-1 and PD-L1 Immunotherapy Basic Information
9.10.2 Eli Lilly PD-1 and PD-L1 Immunotherapy Product Overview
9.10.3 Eli Lilly PD-1 and PD-L1 Immunotherapy Product Market Performance
9.10.4 Eli Lilly Business Overview
9.10.5 Eli Lilly Recent Developments
9.11 GlaxoSmithKline
9.11.1 GlaxoSmithKline PD-1 and PD-L1 Immunotherapy Basic Information
9.11.2 GlaxoSmithKline PD-1 and PD-L1 Immunotherapy Product Overview
9.11.3 GlaxoSmithKline PD-1 and PD-L1 Immunotherapy Product Market Performance
9.11.4 GlaxoSmithKline Business Overview
9.11.5 GlaxoSmithKline Recent Developments
10 PD-1 AND PD-L1 IMMUNOTHERAPY MARKET FORECAST BY REGION
10.1 Global PD-1 and PD-L1 Immunotherapy Market Size Forecast
10.2 Global PD-1 and PD-L1 Immunotherapy Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe PD-1 and PD-L1 Immunotherapy Market Size Forecast by Country
10.2.3 Asia Pacific PD-1 and PD-L1 Immunotherapy Market Size Forecast by Region
10.2.4 South America PD-1 and PD-L1 Immunotherapy Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of PD-1 and PD-L1 Immunotherapy by Country
11 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2030)
11.1 Global PD-1 and PD-L1 Immunotherapy Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of PD-1 and PD-L1 Immunotherapy by Type (2025-2030)
11.1.2 Global PD-1 and PD-L1 Immunotherapy Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of PD-1 and PD-L1 Immunotherapy by Type (2025-2030)
11.2 Global PD-1 and PD-L1 Immunotherapy Market Forecast by Application (2025-2030)
11.2.1 Global PD-1 and PD-L1 Immunotherapy Sales (K Units) Forecast by Application
11.2.2 Global PD-1 and PD-L1 Immunotherapy Market Size (M USD) Forecast by Application (2025-2030)
12 CONCLUSION AND KEY FINDINGS
LIST OF TABLES
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. PD-1 and PD-L1 Immunotherapy Market Size Comparison by Region (M USD)
Table 5. Global PD-1 and PD-L1 Immunotherapy Sales (K Units) by Manufacturers (2019-2024)
Table 6. Global PD-1 and PD-L1 Immunotherapy Sales Market Share by Manufacturers (2019-2024)
Table 7. Global PD-1 and PD-L1 Immunotherapy Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global PD-1 and PD-L1 Immunotherapy Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in PD-1 and PD-L1 Immunotherapy as of 2022)
Table 10. Global Market PD-1 and PD-L1 Immunotherapy Average Price (USD/Unit) of Key Manufacturers (2019-2024)
Table 11. Manufacturers PD-1 and PD-L1 Immunotherapy Sales Sites and Area Served
Table 12. Manufacturers PD-1 and PD-L1 Immunotherapy Product Type
Table 13. Global PD-1 and PD-L1 Immunotherapy Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of PD-1 and PD-L1 Immunotherapy
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. PD-1 and PD-L1 Immunotherapy Market Challenges
Table 22. Global PD-1 and PD-L1 Immunotherapy Sales by Type (K Units)
Table 23. Global PD-1 and PD-L1 Immunotherapy Market Size by Type (M USD)
Table 24. Global PD-1 and PD-L1 Immunotherapy Sales (K Units) by Type (2019-2024)
Table 25. Global PD-1 and PD-L1 Immunotherapy Sales Market Share by Type (2019-2024)
Table 26. Global PD-1 and PD-L1 Immunotherapy Market Size (M USD) by Type (2019-2024)
Table 27. Global PD-1 and PD-L1 Immunotherapy Market Size Share by Type (2019-2024)
Table 28. Global PD-1 and PD-L1 Immunotherapy Price (USD/Unit) by Type (2019-2024)
Table 29. Global PD-1 and PD-L1 Immunotherapy Sales (K Units) by Application
Table 30. Global PD-1 and PD-L1 Immunotherapy Market Size by Application
Table 31. Global PD-1 and PD-L1 Immunotherapy Sales by Application (2019-2024) & (K Units)
Table 32. Global PD-1 and PD-L1 Immunotherapy Sales Market Share by Application (2019-2024)
Table 33. Global PD-1 and PD-L1 Immunotherapy Sales by Application (2019-2024) & (M USD)
Table 34. Global PD-1 and PD-L1 Immunotherapy Market Share by Application (2019-2024)
Table 35. Global PD-1 and PD-L1 Immunotherapy Sales Growth Rate by Application (2019-2024)
Table 36. Global PD-1 and PD-L1 Immunotherapy Sales by Region (2019-2024) & (K Units)
Table 37. Global PD-1 and PD-L1 Immunotherapy Sales Market Share by Region (2019-2024)
Table 38. North America PD-1 and PD-L1 Immunotherapy Sales by Country (2019-2024) & (K Units)
Table 39. Europe PD-1 and PD-L1 Immunotherapy Sales by Country (2019-2024) & (K Units)
Table 40. Asia Pacific PD-1 and PD-L1 Immunotherapy Sales by Region (2019-2024) & (K Units)
Table 41. South America PD-1 and PD-L1 Immunotherapy Sales by Country (2019-2024) & (K Units)
Table 42. Middle East and Africa PD-1 and PD-L1 Immunotherapy Sales by Region (2019-2024) & (K Units)
Table 43. AstraZeneca PD-1 and PD-L1 Immunotherapy Basic Information
Table 44. AstraZeneca PD-1 and PD-L1 Immunotherapy Product Overview
Table 45. AstraZeneca PD-1 and PD-L1 Immunotherapy Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 46. AstraZeneca Business Overview
Table 47. AstraZeneca PD-1 and PD-L1 Immunotherapy SWOT Analysis
Table 48. AstraZeneca Recent Developments
Table 49. Bristol-Myers Squibb PD-1 and PD-L1 Immunotherapy Basic Information
Table 50. Bristol-Myers Squibb PD-1 and PD-L1 Immunotherapy Product Overview
Table 51. Bristol-Myers Squibb PD-1 and PD-L1 Immunotherapy Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 52. Bristol-Myers Squibb Business Overview
Table 53. Bristol-Myers Squibb PD-1 and PD-L1 Immunotherapy SWOT Analysis
Table 54. Bristol-Myers Squibb Recent Developments
Table 55. F. Hoffmann-La Roche PD-1 and PD-L1 Immunotherapy Basic Information
Table 56. F. Hoffmann-La Roche PD-1 and PD-L1 Immunotherapy Product Overview
Table 57. F. Hoffmann-La Roche PD-1 and PD-L1 Immunotherapy Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 58. F. Hoffmann-La Roche PD-1 and PD-L1 Immunotherapy SWOT Analysis
Table 59. F. Hoffmann-La Roche Business Overview
Table 60. F. Hoffmann-La Roche Recent Developments
Table 61. Merck PD-1 and PD-L1 Immunotherapy Basic Information
Table 62. Merck PD-1 and PD-L1 Immunotherapy Product Overview
Table 63. Merck PD-1 and PD-L1 Immunotherapy Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 64. Merck Business Overview
Table 65. Merck Recent Developments
Table 66. Pfizer PD-1 and PD-L1 Immunotherapy Basic Information
Table 67. Pfizer PD-1 and PD-L1 Immunotherapy Product Overview
Table 68. Pfizer PD-1 and PD-L1 Immunotherapy Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 69. Pfizer Business Overview
Table 70. Pfizer Recent Developments
Table 71. Roche PD-1 and PD-L1 Immunotherapy Basic Information
Table 72. Roche PD-1 and PD-L1 Immunotherapy Product Overview
Table 73. Roche PD-1 and PD-L1 Immunotherapy Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 74. Roche Business Overview
Table 75. Roche Recent Developments
Table 76. Novartis PD-1 and PD-L1 Immunotherapy Basic Information
Table 77. Novartis PD-1 and PD-L1 Immunotherapy Product Overview
Table 78. Novartis PD-1 and PD-L1 Immunotherapy Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 79. Novartis Business Overview
Table 80. Novartis Recent Developments
Table 81. Jiangsu HengRui Medicine PD-1 and PD-L1 Immunotherapy Basic Information
Table 82. Jiangsu HengRui Medicine PD-1 and PD-L1 Immunotherapy Product Overview
Table 83. Jiangsu HengRui Medicine PD-1 and PD-L1 Immunotherapy Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 84. Jiangsu HengRui Medicine Business Overview
Table 85. Jiangsu HengRui Medicine Recent Developments
Table 86. Innovent PD-1 and PD-L1 Immunotherapy Basic Information
Table 87. Innovent PD-1 and PD-L1 Immunotherapy Product Overview
Table 88. Innovent PD-1 and PD-L1 Immunotherapy Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 89. Innovent Business Overview
Table 90. Innovent Recent Developments
Table 91. Eli Lilly PD-1 and PD-L1 Immunotherapy Basic Information
Table 92. Eli Lilly PD-1 and PD-L1 Immunotherapy Product Overview
Table 93. Eli Lilly PD-1 and PD-L1 Immunotherapy Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 94. Eli Lilly Business Overview
Table 95. Eli Lilly Recent Developments
Table 96. GlaxoSmithKline PD-1 and PD-L1 Immunotherapy Basic Information
Table 97. GlaxoSmithKline PD-1 and PD-L1 Immunotherapy Product Overview
Table 98. GlaxoSmithKline PD-1 and PD-L1 Immunotherapy Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 99. GlaxoSmithKline Business Overview
Table 100. GlaxoSmithKline Recent Developments
Table 101. Global PD-1 and PD-L1 Immunotherapy Sales Forecast by Region (2025-2030) & (K Units)
Table 102. Global PD-1 and PD-L1 Immunotherapy Market Size Forecast by Region (2025-2030) & (M USD)
Table 103. North America PD-1 and PD-L1 Immunotherapy Sales Forecast by Country (2025-2030) & (K Units)
Table 104. North America PD-1 and PD-L1 Immunotherapy Market Size Forecast by Country (2025-2030) & (M USD)
Table 105. Europe PD-1 and PD-L1 Immunotherapy Sales Forecast by Country (2025-2030) & (K Units)
Table 106. Europe PD-1 and PD-L1 Immunotherapy Market Size Forecast by Country (2025-2030) & (M USD)
Table 107. Asia Pacific PD-1 and PD-L1 Immunotherapy Sales Forecast by Region (2025-2030) & (K Units)
Table 108. Asia Pacific PD-1 and PD-L1 Immunotherapy Market Size Forecast by Region (2025-2030) & (M USD)
Table 109. South America PD-1 and PD-L1 Immunotherapy Sales Forecast by Country (2025-2030) & (K Units)
Table 110. South America PD-1 and PD-L1 Immunotherapy Market Size Forecast by Country (2025-2030) & (M USD)
Table 111. Middle East and Africa PD-1 and PD-L1 Immunotherapy Consumption Forecast by Country (2025-2030) & (Units)
Table 112. Middle East and Africa PD-1 and PD-L1 Immunotherapy Market Size Forecast by Country (2025-2030) & (M USD)
Table 113. Global PD-1 and PD-L1 Immunotherapy Sales Forecast by Type (2025-2030) & (K Units)
Table 114. Global PD-1 and PD-L1 Immunotherapy Market Size Forecast by Type (2025-2030) & (M USD)
Table 115. Global PD-1 and PD-L1 Immunotherapy Price Forecast by Type (2025-2030) & (USD/Unit)
Table 116. Global PD-1 and PD-L1 Immunotherapy Sales (K Units) Forecast by Application (2025-2030)
Table 117. Global PD-1 and PD-L1 Immunotherapy Market Size Forecast by Application (2025-2030) & (M USD)
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. PD-1 and PD-L1 Immunotherapy Market Size Comparison by Region (M USD)
Table 5. Global PD-1 and PD-L1 Immunotherapy Sales (K Units) by Manufacturers (2019-2024)
Table 6. Global PD-1 and PD-L1 Immunotherapy Sales Market Share by Manufacturers (2019-2024)
Table 7. Global PD-1 and PD-L1 Immunotherapy Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global PD-1 and PD-L1 Immunotherapy Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in PD-1 and PD-L1 Immunotherapy as of 2022)
Table 10. Global Market PD-1 and PD-L1 Immunotherapy Average Price (USD/Unit) of Key Manufacturers (2019-2024)
Table 11. Manufacturers PD-1 and PD-L1 Immunotherapy Sales Sites and Area Served
Table 12. Manufacturers PD-1 and PD-L1 Immunotherapy Product Type
Table 13. Global PD-1 and PD-L1 Immunotherapy Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of PD-1 and PD-L1 Immunotherapy
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. PD-1 and PD-L1 Immunotherapy Market Challenges
Table 22. Global PD-1 and PD-L1 Immunotherapy Sales by Type (K Units)
Table 23. Global PD-1 and PD-L1 Immunotherapy Market Size by Type (M USD)
Table 24. Global PD-1 and PD-L1 Immunotherapy Sales (K Units) by Type (2019-2024)
Table 25. Global PD-1 and PD-L1 Immunotherapy Sales Market Share by Type (2019-2024)
Table 26. Global PD-1 and PD-L1 Immunotherapy Market Size (M USD) by Type (2019-2024)
Table 27. Global PD-1 and PD-L1 Immunotherapy Market Size Share by Type (2019-2024)
Table 28. Global PD-1 and PD-L1 Immunotherapy Price (USD/Unit) by Type (2019-2024)
Table 29. Global PD-1 and PD-L1 Immunotherapy Sales (K Units) by Application
Table 30. Global PD-1 and PD-L1 Immunotherapy Market Size by Application
Table 31. Global PD-1 and PD-L1 Immunotherapy Sales by Application (2019-2024) & (K Units)
Table 32. Global PD-1 and PD-L1 Immunotherapy Sales Market Share by Application (2019-2024)
Table 33. Global PD-1 and PD-L1 Immunotherapy Sales by Application (2019-2024) & (M USD)
Table 34. Global PD-1 and PD-L1 Immunotherapy Market Share by Application (2019-2024)
Table 35. Global PD-1 and PD-L1 Immunotherapy Sales Growth Rate by Application (2019-2024)
Table 36. Global PD-1 and PD-L1 Immunotherapy Sales by Region (2019-2024) & (K Units)
Table 37. Global PD-1 and PD-L1 Immunotherapy Sales Market Share by Region (2019-2024)
Table 38. North America PD-1 and PD-L1 Immunotherapy Sales by Country (2019-2024) & (K Units)
Table 39. Europe PD-1 and PD-L1 Immunotherapy Sales by Country (2019-2024) & (K Units)
Table 40. Asia Pacific PD-1 and PD-L1 Immunotherapy Sales by Region (2019-2024) & (K Units)
Table 41. South America PD-1 and PD-L1 Immunotherapy Sales by Country (2019-2024) & (K Units)
Table 42. Middle East and Africa PD-1 and PD-L1 Immunotherapy Sales by Region (2019-2024) & (K Units)
Table 43. AstraZeneca PD-1 and PD-L1 Immunotherapy Basic Information
Table 44. AstraZeneca PD-1 and PD-L1 Immunotherapy Product Overview
Table 45. AstraZeneca PD-1 and PD-L1 Immunotherapy Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 46. AstraZeneca Business Overview
Table 47. AstraZeneca PD-1 and PD-L1 Immunotherapy SWOT Analysis
Table 48. AstraZeneca Recent Developments
Table 49. Bristol-Myers Squibb PD-1 and PD-L1 Immunotherapy Basic Information
Table 50. Bristol-Myers Squibb PD-1 and PD-L1 Immunotherapy Product Overview
Table 51. Bristol-Myers Squibb PD-1 and PD-L1 Immunotherapy Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 52. Bristol-Myers Squibb Business Overview
Table 53. Bristol-Myers Squibb PD-1 and PD-L1 Immunotherapy SWOT Analysis
Table 54. Bristol-Myers Squibb Recent Developments
Table 55. F. Hoffmann-La Roche PD-1 and PD-L1 Immunotherapy Basic Information
Table 56. F. Hoffmann-La Roche PD-1 and PD-L1 Immunotherapy Product Overview
Table 57. F. Hoffmann-La Roche PD-1 and PD-L1 Immunotherapy Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 58. F. Hoffmann-La Roche PD-1 and PD-L1 Immunotherapy SWOT Analysis
Table 59. F. Hoffmann-La Roche Business Overview
Table 60. F. Hoffmann-La Roche Recent Developments
Table 61. Merck PD-1 and PD-L1 Immunotherapy Basic Information
Table 62. Merck PD-1 and PD-L1 Immunotherapy Product Overview
Table 63. Merck PD-1 and PD-L1 Immunotherapy Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 64. Merck Business Overview
Table 65. Merck Recent Developments
Table 66. Pfizer PD-1 and PD-L1 Immunotherapy Basic Information
Table 67. Pfizer PD-1 and PD-L1 Immunotherapy Product Overview
Table 68. Pfizer PD-1 and PD-L1 Immunotherapy Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 69. Pfizer Business Overview
Table 70. Pfizer Recent Developments
Table 71. Roche PD-1 and PD-L1 Immunotherapy Basic Information
Table 72. Roche PD-1 and PD-L1 Immunotherapy Product Overview
Table 73. Roche PD-1 and PD-L1 Immunotherapy Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 74. Roche Business Overview
Table 75. Roche Recent Developments
Table 76. Novartis PD-1 and PD-L1 Immunotherapy Basic Information
Table 77. Novartis PD-1 and PD-L1 Immunotherapy Product Overview
Table 78. Novartis PD-1 and PD-L1 Immunotherapy Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 79. Novartis Business Overview
Table 80. Novartis Recent Developments
Table 81. Jiangsu HengRui Medicine PD-1 and PD-L1 Immunotherapy Basic Information
Table 82. Jiangsu HengRui Medicine PD-1 and PD-L1 Immunotherapy Product Overview
Table 83. Jiangsu HengRui Medicine PD-1 and PD-L1 Immunotherapy Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 84. Jiangsu HengRui Medicine Business Overview
Table 85. Jiangsu HengRui Medicine Recent Developments
Table 86. Innovent PD-1 and PD-L1 Immunotherapy Basic Information
Table 87. Innovent PD-1 and PD-L1 Immunotherapy Product Overview
Table 88. Innovent PD-1 and PD-L1 Immunotherapy Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 89. Innovent Business Overview
Table 90. Innovent Recent Developments
Table 91. Eli Lilly PD-1 and PD-L1 Immunotherapy Basic Information
Table 92. Eli Lilly PD-1 and PD-L1 Immunotherapy Product Overview
Table 93. Eli Lilly PD-1 and PD-L1 Immunotherapy Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 94. Eli Lilly Business Overview
Table 95. Eli Lilly Recent Developments
Table 96. GlaxoSmithKline PD-1 and PD-L1 Immunotherapy Basic Information
Table 97. GlaxoSmithKline PD-1 and PD-L1 Immunotherapy Product Overview
Table 98. GlaxoSmithKline PD-1 and PD-L1 Immunotherapy Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 99. GlaxoSmithKline Business Overview
Table 100. GlaxoSmithKline Recent Developments
Table 101. Global PD-1 and PD-L1 Immunotherapy Sales Forecast by Region (2025-2030) & (K Units)
Table 102. Global PD-1 and PD-L1 Immunotherapy Market Size Forecast by Region (2025-2030) & (M USD)
Table 103. North America PD-1 and PD-L1 Immunotherapy Sales Forecast by Country (2025-2030) & (K Units)
Table 104. North America PD-1 and PD-L1 Immunotherapy Market Size Forecast by Country (2025-2030) & (M USD)
Table 105. Europe PD-1 and PD-L1 Immunotherapy Sales Forecast by Country (2025-2030) & (K Units)
Table 106. Europe PD-1 and PD-L1 Immunotherapy Market Size Forecast by Country (2025-2030) & (M USD)
Table 107. Asia Pacific PD-1 and PD-L1 Immunotherapy Sales Forecast by Region (2025-2030) & (K Units)
Table 108. Asia Pacific PD-1 and PD-L1 Immunotherapy Market Size Forecast by Region (2025-2030) & (M USD)
Table 109. South America PD-1 and PD-L1 Immunotherapy Sales Forecast by Country (2025-2030) & (K Units)
Table 110. South America PD-1 and PD-L1 Immunotherapy Market Size Forecast by Country (2025-2030) & (M USD)
Table 111. Middle East and Africa PD-1 and PD-L1 Immunotherapy Consumption Forecast by Country (2025-2030) & (Units)
Table 112. Middle East and Africa PD-1 and PD-L1 Immunotherapy Market Size Forecast by Country (2025-2030) & (M USD)
Table 113. Global PD-1 and PD-L1 Immunotherapy Sales Forecast by Type (2025-2030) & (K Units)
Table 114. Global PD-1 and PD-L1 Immunotherapy Market Size Forecast by Type (2025-2030) & (M USD)
Table 115. Global PD-1 and PD-L1 Immunotherapy Price Forecast by Type (2025-2030) & (USD/Unit)
Table 116. Global PD-1 and PD-L1 Immunotherapy Sales (K Units) Forecast by Application (2025-2030)
Table 117. Global PD-1 and PD-L1 Immunotherapy Market Size Forecast by Application (2025-2030) & (M USD)
LIST OF FIGURES
Figure 1. Product Picture of PD-1 and PD-L1 Immunotherapy
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global PD-1 and PD-L1 Immunotherapy Market Size (M USD), 2019-2030
Figure 5. Global PD-1 and PD-L1 Immunotherapy Market Size (M USD) (2019-2030)
Figure 6. Global PD-1 and PD-L1 Immunotherapy Sales (K Units) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. PD-1 and PD-L1 Immunotherapy Market Size by Country (M USD)
Figure 11. PD-1 and PD-L1 Immunotherapy Sales Share by Manufacturers in 2023
Figure 12. Global PD-1 and PD-L1 Immunotherapy Revenue Share by Manufacturers in 2023
Figure 13. PD-1 and PD-L1 Immunotherapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market PD-1 and PD-L1 Immunotherapy Average Price (USD/Unit) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by PD-1 and PD-L1 Immunotherapy Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global PD-1 and PD-L1 Immunotherapy Market Share by Type
Figure 18. Sales Market Share of PD-1 and PD-L1 Immunotherapy by Type (2019-2024)
Figure 19. Sales Market Share of PD-1 and PD-L1 Immunotherapy by Type in 2023
Figure 20. Market Size Share of PD-1 and PD-L1 Immunotherapy by Type (2019-2024)
Figure 21. Market Size Market Share of PD-1 and PD-L1 Immunotherapy by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global PD-1 and PD-L1 Immunotherapy Market Share by Application
Figure 24. Global PD-1 and PD-L1 Immunotherapy Sales Market Share by Application (2019-2024)
Figure 25. Global PD-1 and PD-L1 Immunotherapy Sales Market Share by Application in 2023
Figure 26. Global PD-1 and PD-L1 Immunotherapy Market Share by Application (2019-2024)
Figure 27. Global PD-1 and PD-L1 Immunotherapy Market Share by Application in 2023
Figure 28. Global PD-1 and PD-L1 Immunotherapy Sales Growth Rate by Application (2019-2024)
Figure 29. Global PD-1 and PD-L1 Immunotherapy Sales Market Share by Region (2019-2024)
Figure 30. North America PD-1 and PD-L1 Immunotherapy Sales and Growth Rate (2019-2024) & (K Units)
Figure 31. North America PD-1 and PD-L1 Immunotherapy Sales Market Share by Country in 2023
Figure 32. U.S. PD-1 and PD-L1 Immunotherapy Sales and Growth Rate (2019-2024) & (K Units)
Figure 33. Canada PD-1 and PD-L1 Immunotherapy Sales (K Units) and Growth Rate (2019-2024)
Figure 34. Mexico PD-1 and PD-L1 Immunotherapy Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe PD-1 and PD-L1 Immunotherapy Sales and Growth Rate (2019-2024) & (K Units)
Figure 36. Europe PD-1 and PD-L1 Immunotherapy Sales Market Share by Country in 2023
Figure 37. Germany PD-1 and PD-L1 Immunotherapy Sales and Growth Rate (2019-2024) & (K Units)
Figure 38. France PD-1 and PD-L1 Immunotherapy Sales and Growth Rate (2019-2024) & (K Units)
Figure 39. U.K. PD-1 and PD-L1 Immunotherapy Sales and Growth Rate (2019-2024) & (K Units)
Figure 40. Italy PD-1 and PD-L1 Immunotherapy Sales and Growth Rate (2019-2024) & (K Units)
Figure 41. Russia PD-1 and PD-L1 Immunotherapy Sales and Growth Rate (2019-2024) & (K Units)
Figure 42. Asia Pacific PD-1 and PD-L1 Immunotherapy Sales and Growth Rate (K Units)
Figure 43. Asia Pacific PD-1 and PD-L1 Immunotherapy Sales Market Share by Region in 2023
Figure 44. China PD-1 and PD-L1 Immunotherapy Sales and Growth Rate (2019-2024) & (K Units)
Figure 45. Japan PD-1 and PD-L1 Immunotherapy Sales and Growth Rate (2019-2024) & (K Units)
Figure 46. South Korea PD-1 and PD-L1 Immunotherapy Sales and Growth Rate (2019-2024) & (K Units)
Figure 47. India PD-1 and PD-L1 Immunotherapy Sales and Growth Rate (2019-2024) & (K Units)
Figure 48. Southeast Asia PD-1 and PD-L1 Immunotherapy Sales and Growth Rate (2019-2024) & (K Units)
Figure 49. South America PD-1 and PD-L1 Immunotherapy Sales and Growth Rate (K Units)
Figure 50. South America PD-1 and PD-L1 Immunotherapy Sales Market Share by Country in 2023
Figure 51. Brazil PD-1 and PD-L1 Immunotherapy Sales and Growth Rate (2019-2024) & (K Units)
Figure 52. Argentina PD-1 and PD-L1 Immunotherapy Sales and Growth Rate (2019-2024) & (K Units)
Figure 53. Columbia PD-1 and PD-L1 Immunotherapy Sales and Growth Rate (2019-2024) & (K Units)
Figure 54. Middle East and Africa PD-1 and PD-L1 Immunotherapy Sales and Growth Rate (K Units)
Figure 55. Middle East and Africa PD-1 and PD-L1 Immunotherapy Sales Market Share by Region in 2023
Figure 56. Saudi Arabia PD-1 and PD-L1 Immunotherapy Sales and Growth Rate (2019-2024) & (K Units)
Figure 57. UAE PD-1 and PD-L1 Immunotherapy Sales and Growth Rate (2019-2024) & (K Units)
Figure 58. Egypt PD-1 and PD-L1 Immunotherapy Sales and Growth Rate (2019-2024) & (K Units)
Figure 59. Nigeria PD-1 and PD-L1 Immunotherapy Sales and Growth Rate (2019-2024) & (K Units)
Figure 60. South Africa PD-1 and PD-L1 Immunotherapy Sales and Growth Rate (2019-2024) & (K Units)
Figure 61. Global PD-1 and PD-L1 Immunotherapy Sales Forecast by Volume (2019-2030) & (K Units)
Figure 62. Global PD-1 and PD-L1 Immunotherapy Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global PD-1 and PD-L1 Immunotherapy Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global PD-1 and PD-L1 Immunotherapy Market Share Forecast by Type (2025-2030)
Figure 65. Global PD-1 and PD-L1 Immunotherapy Sales Forecast by Application (2025-2030)
Figure 66. Global PD-1 and PD-L1 Immunotherapy Market Share Forecast by Application (2025-2030)
Figure 1. Product Picture of PD-1 and PD-L1 Immunotherapy
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global PD-1 and PD-L1 Immunotherapy Market Size (M USD), 2019-2030
Figure 5. Global PD-1 and PD-L1 Immunotherapy Market Size (M USD) (2019-2030)
Figure 6. Global PD-1 and PD-L1 Immunotherapy Sales (K Units) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. PD-1 and PD-L1 Immunotherapy Market Size by Country (M USD)
Figure 11. PD-1 and PD-L1 Immunotherapy Sales Share by Manufacturers in 2023
Figure 12. Global PD-1 and PD-L1 Immunotherapy Revenue Share by Manufacturers in 2023
Figure 13. PD-1 and PD-L1 Immunotherapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market PD-1 and PD-L1 Immunotherapy Average Price (USD/Unit) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by PD-1 and PD-L1 Immunotherapy Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global PD-1 and PD-L1 Immunotherapy Market Share by Type
Figure 18. Sales Market Share of PD-1 and PD-L1 Immunotherapy by Type (2019-2024)
Figure 19. Sales Market Share of PD-1 and PD-L1 Immunotherapy by Type in 2023
Figure 20. Market Size Share of PD-1 and PD-L1 Immunotherapy by Type (2019-2024)
Figure 21. Market Size Market Share of PD-1 and PD-L1 Immunotherapy by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global PD-1 and PD-L1 Immunotherapy Market Share by Application
Figure 24. Global PD-1 and PD-L1 Immunotherapy Sales Market Share by Application (2019-2024)
Figure 25. Global PD-1 and PD-L1 Immunotherapy Sales Market Share by Application in 2023
Figure 26. Global PD-1 and PD-L1 Immunotherapy Market Share by Application (2019-2024)
Figure 27. Global PD-1 and PD-L1 Immunotherapy Market Share by Application in 2023
Figure 28. Global PD-1 and PD-L1 Immunotherapy Sales Growth Rate by Application (2019-2024)
Figure 29. Global PD-1 and PD-L1 Immunotherapy Sales Market Share by Region (2019-2024)
Figure 30. North America PD-1 and PD-L1 Immunotherapy Sales and Growth Rate (2019-2024) & (K Units)
Figure 31. North America PD-1 and PD-L1 Immunotherapy Sales Market Share by Country in 2023
Figure 32. U.S. PD-1 and PD-L1 Immunotherapy Sales and Growth Rate (2019-2024) & (K Units)
Figure 33. Canada PD-1 and PD-L1 Immunotherapy Sales (K Units) and Growth Rate (2019-2024)
Figure 34. Mexico PD-1 and PD-L1 Immunotherapy Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe PD-1 and PD-L1 Immunotherapy Sales and Growth Rate (2019-2024) & (K Units)
Figure 36. Europe PD-1 and PD-L1 Immunotherapy Sales Market Share by Country in 2023
Figure 37. Germany PD-1 and PD-L1 Immunotherapy Sales and Growth Rate (2019-2024) & (K Units)
Figure 38. France PD-1 and PD-L1 Immunotherapy Sales and Growth Rate (2019-2024) & (K Units)
Figure 39. U.K. PD-1 and PD-L1 Immunotherapy Sales and Growth Rate (2019-2024) & (K Units)
Figure 40. Italy PD-1 and PD-L1 Immunotherapy Sales and Growth Rate (2019-2024) & (K Units)
Figure 41. Russia PD-1 and PD-L1 Immunotherapy Sales and Growth Rate (2019-2024) & (K Units)
Figure 42. Asia Pacific PD-1 and PD-L1 Immunotherapy Sales and Growth Rate (K Units)
Figure 43. Asia Pacific PD-1 and PD-L1 Immunotherapy Sales Market Share by Region in 2023
Figure 44. China PD-1 and PD-L1 Immunotherapy Sales and Growth Rate (2019-2024) & (K Units)
Figure 45. Japan PD-1 and PD-L1 Immunotherapy Sales and Growth Rate (2019-2024) & (K Units)
Figure 46. South Korea PD-1 and PD-L1 Immunotherapy Sales and Growth Rate (2019-2024) & (K Units)
Figure 47. India PD-1 and PD-L1 Immunotherapy Sales and Growth Rate (2019-2024) & (K Units)
Figure 48. Southeast Asia PD-1 and PD-L1 Immunotherapy Sales and Growth Rate (2019-2024) & (K Units)
Figure 49. South America PD-1 and PD-L1 Immunotherapy Sales and Growth Rate (K Units)
Figure 50. South America PD-1 and PD-L1 Immunotherapy Sales Market Share by Country in 2023
Figure 51. Brazil PD-1 and PD-L1 Immunotherapy Sales and Growth Rate (2019-2024) & (K Units)
Figure 52. Argentina PD-1 and PD-L1 Immunotherapy Sales and Growth Rate (2019-2024) & (K Units)
Figure 53. Columbia PD-1 and PD-L1 Immunotherapy Sales and Growth Rate (2019-2024) & (K Units)
Figure 54. Middle East and Africa PD-1 and PD-L1 Immunotherapy Sales and Growth Rate (K Units)
Figure 55. Middle East and Africa PD-1 and PD-L1 Immunotherapy Sales Market Share by Region in 2023
Figure 56. Saudi Arabia PD-1 and PD-L1 Immunotherapy Sales and Growth Rate (2019-2024) & (K Units)
Figure 57. UAE PD-1 and PD-L1 Immunotherapy Sales and Growth Rate (2019-2024) & (K Units)
Figure 58. Egypt PD-1 and PD-L1 Immunotherapy Sales and Growth Rate (2019-2024) & (K Units)
Figure 59. Nigeria PD-1 and PD-L1 Immunotherapy Sales and Growth Rate (2019-2024) & (K Units)
Figure 60. South Africa PD-1 and PD-L1 Immunotherapy Sales and Growth Rate (2019-2024) & (K Units)
Figure 61. Global PD-1 and PD-L1 Immunotherapy Sales Forecast by Volume (2019-2030) & (K Units)
Figure 62. Global PD-1 and PD-L1 Immunotherapy Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global PD-1 and PD-L1 Immunotherapy Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global PD-1 and PD-L1 Immunotherapy Market Share Forecast by Type (2025-2030)
Figure 65. Global PD-1 and PD-L1 Immunotherapy Sales Forecast by Application (2025-2030)
Figure 66. Global PD-1 and PD-L1 Immunotherapy Market Share Forecast by Application (2025-2030)
